It also blocked AKT activity, and the authors confirmed selectivity to the Wnt pathway by assessing other cancer-related pathways, NICD1 and GLI1, which were not affected, and also by loss-of-compound effects upon β-catenin knockdown [122]. This evidence concerns the gene AKT1 and cancer.